





PHARMACEUTICAL 2023

ELI LILLY & Co
Rank 249 of 446



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 14% points above the market average of 43%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 18,034,500 |
| Cost of Goods Sold | 6,629,800 |
| Intangible Assets | 11,279,600 |
| Liabilities, Current | 17,138,200 |
| Liabilities, Non-Current | 21,576,200 |
| Other Assets | 10,031,700 |
| Other Compr. Net Income | 498,500 |
| Other Expenses | 2,035,600 |
| Other Liabilities | 0 |
| Other Net Income | 0 |
| Other Revenues | 28,541,400 |
| Property and Equipment | 10,144,000 |
| Research and Development | 7,190,800 |
| Selling, General and Administrative Expense | 6,440,400 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 49,489,800 |
| Liabilities | 38,714,400 |
| Expenses | 22,296,600 |
| Revenues | 28,541,400 |
| Stockholders Equity | 10,775,400 |
| Net Income | 6,244,800 |
| Comprehensive Net Income | 6,494,050 |
| Economic Capital Ratio | 57% |